leisure time -WSS

leisure time

author：Wikipedia 2025-10-02 19:55:27 - browse：7

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Some medical students still think black patients feel less pain

WSS

Should insurance cover cosmetic surgery?

Biogen walks away from Aduhelm, years after polarizing approval

Some medical students still think black patients feel less pain

Why you shouldn’t ask, “What country has the best health care?”

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Pharma’s losing bet in New Jersey

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Medicare details structure of new drug price negotiation program

Asahi Kasei to buy Calliditas, picking up kidney disease drug

Guidelines to prevent youth baseball injuries need more muscle

Unmasking the 'centricity' illusion in clinical trials

How to save PrEP access — and even expand it

The Bio Revolution is changing business and society

Activists slam private health insurers over coverage restrictions

Decentralized clinical trials need collaboration to achieve wider use

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Stroke rates rising, especially in working

focus

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Medical students need to learn the potent medicine of empathy

Lawsuit challenges CMS nursing home minimum staffing rule

Lawsuit challenges CMS nursing home minimum staffing rule

Protect nursing home residents from future pandemics

Lawsuit challenges CMS nursing home minimum staffing rule

hotspot

hotspot

hotspot

entertainment